Stop Corporate Inversions Act of 2026

The Stop Corporate Inversions Act of 2026 (S3847) was introduced in the Senate on February 11, 2026, and subsequently referred to the Committee on Finance. This bill seeks to amend the Internal Revenue Code of 1986 to modify rules relating to inverted corporations, specifically by treating more foreign corporations as domestic for tax purposes if they meet certain criteria, such as having more than 50 percent of stock held by former U.S. shareholders or having management and control primarily within the United States. The bill's intent is to eliminate a key tax avoidance strategy, directly increasing tax burdens for corporations that have completed inversions after May 8, 2014, or are considered inverted domestic corporations under the new definitions. This bill does not authorize or appropriate any direct funding. Instead, its mechanism is regulatory, aiming to increase tax revenue for the U.S. government by reclassifying certain foreign corporations as domestic for tax purposes. This would directly impact the net income of companies that have previously engaged in corporate inversions to reduce their U.S. tax liability. The financial impact would be through increased tax payments rather than direct government spending or grants. Structural losers under this proposed legislation include companies that have completed corporate inversions or have significant foreign operations structured to minimize U.S. tax exposure. Examples of companies that have previously undergone inversions or have significant international structures include Medtronic plc ($MDT), Perrigo Company plc ($PRGO), Allegion plc ($ALLE), and CRH plc ($CRH). While Pfizer Inc. ($PFE) previously attempted an inversion, its current structure would still be affected by the broader implications of increased scrutiny on foreign-domiciled entities with substantial U.S. ties. The Estée Lauder Companies Inc. ($EL) and Stryker Corporation ($SYK) also have significant international operations that could face increased tax scrutiny if the bill's definitions are broadly applied. Medtronic plc ($MDT) has seen a -5.9% change over the last 30 days, and Perrigo Company plc ($PRGO) a -1.03% change over the same period. Allegion plc ($ALLE) is down -6.8% over 30 days, and CRH plc ($CRH) is down -1.79% over 30 days. The Estée Lauder Companies Inc. ($EL) has experienced a significant -25.23% change over the last 30 days. These movements suggest market sensitivity to factors that could impact international operations or tax structures. As of April 7, 2026, the bill is in its early legislative stage, having been referred to the Senate Committee on Finance. There is a companion bill, HR7493, in the House, which increases the probability of legislative progress. The presence of nine cosponsors, including Senator Durbin, indicates some support within the Senate. However, the bill must pass through committee, be voted on by the full Senate, then pass the House, and finally be signed by the President to become law. This process can take months or years, and the bill may undergo significant changes.